Immunohistochemical Evaluation of FGD3 Expression: A New Strong Prognostic Factor in Invasive Breast Cancer
Open Access
Abstract
Among new prognostic factors for breast cancer, the most promising one seems to be FGD3 (Facio-Genital Dysplasia 3) gene, whose expression improves outcome by inhibiting cell migration. The aim of the study was to evaluate the prognostic role of FGD3 in invasive breast cancer in a series of 401 women, treated at our unit, by evaluating the expression of this gene by immunohistochemistry. Patients with high FGD3 expression showed a significantly better disease-free survival (DFS) (p < 0.001) and overall survival (OS) (p < 0.001). The prognostic value of FGD3 expression was stronger than that of classical pathologic parameters such as histological grade of differentiation, Ki-67 index and molecular subtype. By multivariate Cox analysis, FGD3 expression was confirmed as significant and independent prognostic factor, ranking second after age at diagnosis (≤40 years) for DFS (p = 0.003) and the second strongest predictor of OS, after AJCC Stage (p < 0.001). Our data suggest that inclusion of FGD3 evaluation in the routine workup of breast cancer patients may result in a more accurate stratification of the individual risk. The possibility to assess FGD3 expression by a simple and cheap technique such as immunohistochemistry may enhance the spread of its use in the clinical practice.Keywords
This publication has 30 references indexed in Scilit:
- Effect of Breast Conservation Therapy vs Mastectomy on Disease-Specific Survival for Early-Stage Breast CancerJAMA Surgery, 2014
- Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast CancerScience Translational Medicine, 2013
- Development of a Prognostic Model for Breast Cancer Survival in an Open Challenge EnvironmentScience Translational Medicine, 2013
- The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancerEuropean Journal of Cancer, 2012
- Patients 35 years old or younger with operable breast cancer are more at risk for relapse and survival: A retrospective matched case–control studyThe Breast, 2011
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI: Journal of the National Cancer Institute, 2011
- Novel insights into FGD3, a putative GEF for Cdc42, that undergoes SCFFWD1/β‐TrCP‐mediated proteasomal degradation analogous to that of its homologue FGD1 but regulates cell morphology and motility differently from FGD1Genes to Cells, 2008
- Tamoxifen in the Treatment of Breast CancerNew England Journal of Medicine, 1998
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studiesThe Lancet, 1996